Program - Society of Toxicology
Program - Society of Toxicology
Program - Society of Toxicology
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
44 th Annual Meeting<br />
and ToxExpo<br />
<strong>Program</strong> Description<br />
Tuesday Morning, March 8<br />
9:30 AM to 12:30 PM<br />
Exhibit Hall<br />
POSTER SESSION: SAFETY EVALUATION-BIOTECHNOLOGY<br />
PRODUCTS AND VACCINES<br />
Displayed: 9:30 AM–12:30 PM<br />
Attended: 11:00 AM–12:30 PM<br />
#797 VALIDATION OF REAL TIME QUANTITATIVE<br />
PCR AND SAMPLE PREPARATION<br />
PROCEDURE IN BIODISTRIBUTION STUDY OF<br />
ADENOVIRUS VECTORS. B. Tian, S. S. Rentz, G. S.<br />
Gregory, R. Tina and J. G. Page. Southern Research<br />
Institute, Birmingham, AL.<br />
#798 SINGLE-DOSE TOXICITY STUDY OF AN<br />
ONCOLYTIC ADENOVIRUS ADMINISTERED BY<br />
INTRAVENOUS INFUSION TO CYNOMOLGUS<br />
MONKEYS. B. McIntyre 1 , S. Thibault 1 , N. Kishnani 2 ,<br />
D. Compton 1 , R. Veneziale 1 , J. Nelson 3 , R. Ralston 4,2<br />
and R. Morrissey 1 . 1 Schering-Plough Research Institute,<br />
Lafayette, NJ, 2 Schering-Plough Research Institute,<br />
Kenilworth, NJ, 3 Charles River Laboratories, Sierra<br />
Division, Sparks, NV and 4 Canji, San Diego, CA.<br />
#799 FIFTEEN-MONTH REPEATED DOSE<br />
SUBCUTANEOUS ADMINISTRATION STUDY OF<br />
RHFGF-2 IN ATHYMIC NUDE MICE. S. Tsunoda 1 ,<br />
T. Nakamura 1 , T. Sibanushi 1 , K. Kuzutani 1 and M.<br />
Takahashi 2 . 1 Safety Research Department, Kaken<br />
Pharmaceutical co., Ltd., Sizuoka, Japan and 2 Pathology<br />
Peer Review Center, Tokyo, Japan.<br />
#800 PRECLINICAL SAFETY OF RECOMBINANT<br />
HUMAN THROMBIN. J. K. Heffernan, R. Ponce, L.<br />
A. Zuckerman, J. Visich and M. Rogge. Preclinical<br />
Development, ZymoGenetics, Seattle, WA.<br />
#801 SAFETY ASSESSMENT OF MONOCLONAL<br />
ANTIBODY MAB216 + VINCRISTINE IN<br />
RABBITS. K. Steinmetz 1 , D. Fairchild 1 , N. Teng 2 , M.<br />
Bieber 2 , K. Schweikart 3 , J. Tomaszewski 3 and J.<br />
Mirsalis 1 . 1 SRI International, Menlo Park, CA,<br />
2 3 Stanford University, Stanford, CA and National<br />
Cancer Institute, Bethesda, MD.<br />
#802 RISING DOSE TOLERABILITY STUDIES OF A<br />
CHIMERIC ANTI-PHOSPHATIDYLSERINE<br />
MONOCLONAL ANTIBODY (TARVACIN) IN<br />
RATS AND CYNOMOLGUS MONKEYS. S.<br />
Carpenter 1 , C. Stewart 2 , L. Willis 2 and P. E. Thorpe 3 .<br />
1 2 Peregrine Pharmaceuticals, Inc., Tustin, CA, MPI<br />
Research, Inc., Mattawan, MI and 3 The University <strong>of</strong><br />
Texas Southwestern, Dallas, TX.<br />
#803 SAFETY EVALUATION OF A CHIMERIC ANTI-<br />
PHOSPHATIDYLSERINE MONOCLONAL<br />
ANTIBODY (TARVACIN) IN MICE USING A<br />
FULL-THICKNESS EXCISIONAL DERMAL<br />
WOUND MODEL. S. Carpenter 1 , T. Nguyen 2 and P.<br />
E. Thorpe 3 . 1 Peregrine Pharmaceuticals, Inc., Tustin,<br />
CA, 2 Explora Biolabs, LLC, La Jolla, CA and 3 The<br />
University <strong>of</strong> Texas Southwestern, Dallas, TX. Sponsor:<br />
L. Kamendulis.<br />
#804 REPRODUCTIVE AND DEVELOPMENTAL<br />
EFFECTS OF AVASTIN, A MONOCLONAL<br />
ANTIBODY AGAINST VASCULAR<br />
ENDOTHELIAL GROWTH FACTOR. C. L. Zuch 1 ,<br />
A. Bricarello 2 , J. C. Beyer 1 , P. J. Thomford 3 , B. J.<br />
Christian 3 and A. M. Hoberman 4 . 1 Safety Assessment,<br />
Genentech, Inc., South San Francisco, CA, 2 Study<br />
Management, Genentech, Inc., South San Francisco,<br />
CA, 3 Covance Laboratories, Inc., Madison, WI and<br />
4 Charles River Laboratories, Inc., Argus Research<br />
Division, Horsham, PA.<br />
#805 ACUTE TOXICITY STUDIES WITH A<br />
TRANSFORMING GROWTH FACTOR-BETA<br />
ANTAGONIST IN SPRAGUE-DAWLEY RATS<br />
AND CYNOMOLGUS MONKEYS. E. R. LaCasse,<br />
R. Pawliuk, J. DelCarpini, C. Rogers and L. Andrews.<br />
Pharmacology/<strong>Toxicology</strong>, Genzyme, Framingham,<br />
MA.<br />
#806 SAFETY EVALUATION OF A HUMAN FUSION<br />
PROTEIN PRO97796 (BR3-FC). T. R. Gelzleichter 1 ,<br />
T. Kamenosono 2 , D. M. Danilenko 1 , S. Ren 1 , A. Song 1 ,<br />
S. R. Brignoli 1 , T. M. Watson 1 and Y. Vugmeyster 1 .<br />
1 2 Genentech, South San Francisco, CA and SNBL,<br />
USA, Seattle, WA.<br />
#807 CJC-1295, A LONG-ACTING GROWTH<br />
HORMONE RELEASE FACTOR ANALOGUE, IS<br />
WELL TOLERATED IN DOGS UP TO 14 DAYS. V.<br />
Iordanova 1 , S. Wen 1 , B. Lawrence 1 , C. N. Papagiannis 2 ,<br />
S. Morseth 3 and J. Castaigne 1 . 1 ConjuChem, Inc.,<br />
Montreal, QC, Canada, 2 MPI Research, Inc., Mattawan,<br />
MI and 3 Morseth Consulting LLC, Jefferson, MD.<br />
#808 RODENT SUBCHRONIC TOXICITY STUDIES<br />
WITH THE PEPTIDE ANTIBIOTIC XMP.629. R.<br />
Hawks 1 , S. W. Frantz 2 , J. T. Secrest 2 and K. E. Meyer 1 .<br />
1 2 XOMA LLC, Berkeley, CA and MPI Research,<br />
Mattawan, MI.<br />
#809 SAFETY AND EFFICACY OF GLYCOSYLATED<br />
UNDENATURED TYPE II COLLAGEN (UC-II) IN<br />
OBESE-ARTHRITIC DOGS. R. C. Gupta 1 , L.<br />
DeParle 1 , T. Canerdy 1 , J. Goad 1 , M. Bagchi 2 and D.<br />
Bagchi 2 . 1 <strong>Toxicology</strong>, Murray State university,<br />
Hopkinsville, KY and 2 InterHealth Nutraceuticals Inc.,<br />
Benicia, CA.<br />
#810 PRECLINICAL SAFETY ASSESSMENT OF<br />
RECOMBINANT PLAGUE VACCINE (RF1V)<br />
FOLLOWING REPEAT-DOSE<br />
ADMINISTRATION. R. V. House 1 , J. Shearer 1 , S.<br />
Manetz 2 and S. Morris 1 . 1 DynPort Vaccine Company<br />
LLC, Frederick, MD and 2 Gene Logic Laboratories,<br />
Gaithersburg, MD.<br />
#811 PRECLINICAL SAFETY ASSESSMENT OF<br />
RECOMBINANT BOTULINUM VACCINE A/B<br />
(RBV A/B) FOLLOWING REPEAT-DOSE<br />
ADMINISTRATION. J. Shearer 1 , I. Henderson 1 , S.<br />
Manetz 2 and R. V. House 1 . 1 DynPort Vaccine Company<br />
LLC, Frederick, MD and 2 Gene Logic Laboratories.<br />
Inc., Gaithersburg, MD.<br />
TUESDAY<br />
up-to-date information at www.toxicology.org 111